Erratum to: Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study: Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions (International Journal of Cancer, (2016), 138, 12, (2867-2874), 10.1002/ijc.30035);Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study

International Journal of Cancer

Volumn 138, Issue 12, 2016, Pages 2867-2874

  Herweijer, Eva ^a   Sundström, Karin ^a   Ploner, Alexander ^a   Uhnoo, Ingrid ^b   Sparén, Pär ^a   Arnheim Dahlström, Lisen ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

high grade cervical lesions; HPV vaccination; nationwide; vaccine effectiveness

Indexed keywords

WART VIRUS VACCINE; VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PARENTING EDUCATION; POPULATION RESEARCH; PRIORITY JOURNAL; SWEDEN; UTERINE CERVIX CARCINOMA IN SITU; AGE DISTRIBUTION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINE POTENCY; YOUNG ADULT;

EID: 84960389187     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30721     Document Type: Erratum

References (27)

1. Bruni L, Barrionuevo-Rosas L, Serrano B, et al., Human Papillomavirus and Related Diseases in the World. Summary Report 2014-08-22. ICO Information Centre on HPV and Cancer (HPV Information Centre).
2. Vaccarella S, Franceschi S, Engholm G, et al., 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014; 111: 965-9.
3. Clifford G, Franceschi S, Diaz M, et al., Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24: S26-34.
4. Muñoz N, Bosch FX, Castellsagué X, et al., Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 2004; 111: 278-85.
5. Guan P, Howell-Jones R, Li N, et al., Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
6. Baandrup L, Munk C, Andersen KK, et al., HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 2012; 124: 281-5.
7. Brismar-Wendel S, Froberg M, Hjerpe A, et al., Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 2009; 101: 511-7.
8. NKCx [Internet]. Available at: http://www.nkcx.se/index-e.htm. (Accessed on July 1, 2015).
9. Greer CE, Wheeler CM, Ladner MB, et al., Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33: 2058-63.
10. Garland SM, Steben M, Sings HL, et al., Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199: 805-14.
11. PowerPoint Presentation-HPV-vaccination-tom-14-12-31.pdf. Available at: http://www.folkhalsomyndigheten.se/documents/smittskydd-sjukdomar/vaccinationer/HPV-vaccination-tom-14-12-31.pdf. (Accessed on July 1, 2015).
12. Baldur-Felskov B, Dehlendorff C, Munk C, et al., Early impact of human papillomavirus vaccination on cervical neoplasia-Nationwide Follow-up of Young Danish Women. J Natl Cancer Inst 2014; 106: djt460.
13. Gertig DM, Brotherton JM, Budd AC, et al., Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11: 227.
14. Mahmud SM, Kliewer EV, Lambert P, et al., Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol 2014; 32: 438-43.
15. Powell SE, Hariri S, Steinau M, et al., Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31: 109-13.
16. Crowe E, Pandeya N, Brotherton JML, et al., Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348: g1458.
17. Barlow L, Westergren K, Holmberg L, et al., The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol 2009; 48: 27-33.
18. Swedish Cancer Registry. Available at: about:reader?url=http%3A%2F%2F www.socialstyrelsen.se%2Fregister%2Fhalsodataregister%2Fcancerregistret%2Finenglish. (Accessed on June 5, 2015)
19. Läkemedelsregistret [Internet]. Available at: http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret. (Accessed on June 24, 2015).
20. Leval A, Herweijer E, Ploner A, et al., Quadrivalent human papillomavirus vaccine effectiveness: a Swedish National Cohort Study. J Natl Cancer Inst 2013; 105: 469-74.
21. Hildesheim A, Herrero R, Wacholder S, et al., Effect of human papillomavirus 16/18 l1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-53.
22. Haupt RM, Wheeler CM, Brown DR, et al., Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 2011; 129: 2632-42.
23. Hariri S, Bennett NM, Niccolai LM, et al., Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States-2008-2012. Vaccine 2015; 33: 1608
24. Winer RL, Feng Q, Hughes JP, et al., Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197: 279-82.
25. Castellsagué X, Paavonen J, Jaisamrarn U, et al., Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infect Dis 2014; 14: 551
26. Jensen KE, Munk C, Sparen P, et al., Women's sexual behavior. Population-based study among 65 000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand 2011; 90: 459-67.
27. Herweijer E, Feldman AL, Ploner A, et al., The participation of HPV-vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS One 2015; 10: e0134185.